Adherence and perceived barriers to oral antiviral therapy for chronic hepatitis B

Background: Globally, of the 248 million people chronically infected with the hepatitis B virus (HBV), 74 million reside in China. Five oral nucleot(s)ide analogs (NUCs) have been approved for the treatment of chronic hepatitis B (CHB) in China. Objectives: The aims of this study were to determine r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kerui Xu, Li-Ming Liu, Paraskevi A. Farazi, Hongmei Wang, Fedja A Rochling, Shinobu Watanabe-Galloway, Jian-Jun Zhang
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2018-01-01
Colecção:Global Health Action
Assuntos:
China
chronic hepatitis B
nucleot(s)ide analogs
medication adherence
Morisky Medication Adherence Scale
Acesso em linha:http://dx.doi.org/10.1080/16549716.2018.1433987
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados